CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of “Moderate Buy” from Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE acquired a new stake in CytomX Therapeutics in the 3rd quarter valued at about $40,000. XTX Topco Ltd increased its position in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the period. Forefront Analytics LLC raised its stake in CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 40,309 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of CytomX Therapeutics during the 3rd quarter worth $104,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX opened at $1.13 on Friday. The firm has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.19. The stock has a market cap of $88.43 million, a P/E ratio of 6.65 and a beta of 1.07. CytomX Therapeutics has a 52-week low of $0.83 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same quarter last year, the firm posted $0.04 earnings per share. Analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.